|
Cai, Yi; Hirata, Ayako; Nakayama, Sohei et al. (2015) CCAAT/enhancer binding protein ? is dispensable for development of lung adenocarcinoma. PLoS One 10:e0120647
|
|
Nakayama, Sohei; Sng, Natasha; Carretero, Julian et al. (2014) ?-catenin contributes to lung tumor development induced by EGFR mutations. Cancer Res 74:5891-902
|
|
Yamaguchi, Norihiro; Lucena-Araujo, Antonio R; Nakayama, Sohei et al. (2014) Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer 83:37-43
|
|
Kobayashi, Susumu; Canepa, Hannah M; Bailey, Alexandra S et al. (2013) Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8:45-51
|
|
Yasuda, Hiroyuki; Park, Eunyoung; Yun, Cai-Hong et al. (2013) Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 5:216ra177
|
|
Yasuda, Hiroyuki; de Figueiredo-Pontes, Lorena L; Kobayashi, Susumu et al. (2012) Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 7:1086-90
|
|
Yasuda, Hiroyuki; Kobayashi, Susumu; Costa, Daniel B (2012) EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 13:e23-31
|
|
Will, Britta; Siddiqi, Tanya; Jordà , Meritxell Alberich et al. (2010) Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood 115:2901-9
|
|
Costa, Daniel B; Kobayashi, Susumu; Yeo, Wee-Lee et al. (2010) Serum concentrations of Erlotinib at a dose of 25 mg daily. J Thorac Oncol 5:1311-2
|
|
Zhang, Zhenfeng; Stiegler, Amy L; Boggon, Titus J et al. (2010) EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1:497-514
|
Showing the most recent 10 out of 13 publications
